S&P 500Health Care· USA

INCY

Dependent

Incyte

$95.55

-0.55%

Open $96.13·Prev $96.08

as of 13 Apr

DEPENDENT

Power Core

Moat in one sentence: Incyte's moat is its first-mover dominance in selective JAK1/JAK2 inhibition for myeloproliferative neoplasms, reinforced by physician entrenchment, real-world evidence accumulation, and regulatory exclusivities that create a switching-cost barrier for a patient population with limited therapeutic alternatives.

Published1 Apr 2026

UniverseS&P 500

SectorHealth Care

↑

Direction of Movement

Lateral with Mounting Downward Pressure on the Horizon

ROC 200

+34.7%

Financials